International Patent: AN ENGINEERED CELL COMPRISING AN ANTI-CD19 AND ANTI-CD20 CHIMERIC ANTIGEN RECEPTOR, A NUCLEIC ACID OR VECTOR, A KIT AND THEIR USE

GENEVA, July 6 -- AVENCELL THERAPEUTICS INC. filed a patent application (IB2025/063221) for “AN ENGINEERED CELL COMPRISING AN ANTI-CD19 AND ANTI-CD20 CHIMERIC ANTIGEN RECEPTOR, A NUCLEIC ACID OR VECTOR, A KIT AND THEIR USE”. With publication no. WO/2026/139825, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: C07K 16/28

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....